Introgen's 'Promise'

Introgen Therapeutics(INGN Quote) has accused me of being "false and misleading" because of some sharply worded columns in which I detail the ways the company has misled investors about its development of the cancer gene therapy Advexin.

So far, Introgen hasn't detailed how I've been false and misleading, and the company has never contacted me or asked TheStreet.com for a correction. But on Thursday, Introgen will hold a conference call to discuss its fourth-quarter results. On that call, the company has promised to comment further.

Good. It should be a fun call. To get ready for it, I read through transcripts of Introgen conference calls going back four years. Below is a timeline of sorts, complete with excerpts that detail the many ways in which the Advexin story has changed over the years. ...